CT引导下经皮穿刺植入放射性^(125)I粒子治疗肺癌的临床应用  

Clinical application of ^(125)I seed implantation in lung carcinoma guided by CT

作　　者：王玉君[1] 崔亚利[1] 余红波[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院核医学科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2006年第5期386-388,共3页Practical Oncology Journal

摘　　要：目的探讨CT引导下经皮穿刺植入放射性125I粒子的肺癌治疗方法,观察临床疗效和不良反应。方法于2004年6月-2005年10月,经CT引导125I粒子植入治疗肺癌32例。所有病例均行术前TPS制定治疗计划,术后质量验证。全部患者均植入0.5mCi-1.0mCi的放射性粒子,12-60颗。结果植入病例全部成功,无死亡,部分出现气胸、出血,术后1周复查外周血象、1月复查CT及临床观察无毒副反应,术后定期复查CT,未出现放射损伤症状,未发现粒子脱落或游走等并发症。CR22.58%、PR61.29%、SD12.9%、PD3.2%。中位生存期大于12个月。结论CT引导下经皮穿刺放射性125I粒子近距离照射治疗肺癌安全、有效,并且创伤小、并发症少。Objective To explore the therapy method of ^125I seed implantation in hmg careinorma guided by CT and to observe the clinical effect and adverse response. Methods From June, 2004 to October, 2005, 32 patients with lung carcinoma accepting CT guided radioactive seed ^125I implanlation were enrolled in this study. All cases were performed according to the treatment planning system （TPS） before, operation, then the radioactive dose was validated, Every patient was implanted into radioactive seed of 0.5 mci - 1.0 mci in does and 12 - 60 in quantities. Results All implantation cases were satisfaetive, no death occurred, but pnevanothorax and blooding in partial cases. There is no toxic l＇espense in reexamination of peripheral blood hemogram one week after treatment, of CT one month after operation and clinical observation; whereas periodic CT found no symptom of radioactive trauma and no complication of dropping, migrating and so on. Among lung carcinoma in 32 patients, 22.58% obtained CR, 61.29% obtained PR, 12.9% CD and 3.2% PD. Mediam survival time （MST） was more than 12 months. Conclusion The brachytherapy of ^125I seed implantation in lung carcinoma guided by CT is safe and effective, with less traumas and complications.

关 键 词：^125I粒子 近距离照射 肺癌 CT 植入 

分 类 号：R734.2[医药卫生—肿瘤]